$
31.670
+0.17(0.540%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
31.670
Open
31.670
VWAP
--
Vol
884.00
Mkt Cap
1.35B
Low
31.670
Amount
--
EV/EBITDA(TTM)
38.67
Total Shares
41.73M
EV
1.63B
EV/OCF(TTM)
150.88
P/S(TTM)
3.38
Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons’ challenges in treating patients with aortic diseases. The Company is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Its Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. Its Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include its BioGlue Surgical Adhesive products.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
112.88M
+16.01%
--
--
107.45M
+12.18%
--
--
107.95M
+10.14%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Artivion, Inc. (AORT) for FY2025, with the revenue forecasts being adjusted by -0.08% over the past three months. During the same period, the stock price has changed by 33.69%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.08%
In Past 3 Month
Stock Price
Go Up
up Image
+33.69%
In Past 3 Month
5 Analyst Rating
up Image
4.20% Upside
Wall Street analysts forecast AORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AORT is 33.00 USD with a low forecast of 30.00 USD and a high forecast of 35.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
up Image
4.20% Upside
Current: 31.670
sliders
Low
30.00
Averages
33.00
High
35.00
Canaccord
William Plovanic
Buy
initiated
$35
2025-06-18
Reason
Canaccord analyst William Plovanic initiated coverage of Artivion with a Buy rating and $35 price target. The company is a "highly focused player" in cardiac surgery "with bets about to pay off" for aortic arch repair, the analyst tells investors in a research note. The firm says Artivion is a leading player in aortic and abdominal graft, mechanical and bioprosthetic tissue valves, and surgical sealants and sells its products to cardiac and vascular surgeons. Canaccord believes the company has made several bets on the aortic arch repair space that are on the verge of paying off, including the acquisitions of Jotec in 2017 and Acyrus Medical in 2020, and a distribution and purchase option for Endospan in 2019. Over the next few years, both AMDS and Nexus should bolster Artivion's sales growth and drive continued leverage for even faster adjusted EBITDA growth, contends Canaccord.
Needham
Mike Matson
Strong Buy
Reiterates
$34
2025-01-28
Reason
JMP Securities
Daniel Stauder
Buy
Reiterates
$33
2024-12-10
Reason
Needham
Mike Matson
Strong Buy
Reiterates
$34
2024-12-09
Reason
Oppenheimer
Suraj Kalia
Buy
Maintains
$30 → $32
2024-11-08
Reason
JMP Securities
Daniel Stauder
Buy
Initiates
$33
2024-10-23
Reason
JMP Securities initiated coverage of Artivion with an Outperform rating and $33 price target. Artivion is a cardiovascular-focused medical technologies company with leading aortic-centric solutions, including valve replacements and stent grafts for treating dissections and aneurysms, the analyst tells investors in a research note. The firm views the company as a "unique small cap name worth owning," citing its "dependable" base business, complementary advanced stent graft division, EBITDA growth and margin profile, and potential upside from "notable shots on goal slated for the years ahead."

Valuation Metrics

The current forward P/E ratio for Artivion Inc (AORT.N) is 161.56, compared to its 5-year average forward P/E of 115.89. For a more detailed relative valuation and DCF analysis to assess Artivion Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
115.89
Current PE
161.56
Overvalued PE
1306.63
Undervalued PE
-1074.85

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
21.17
Current EV/EBITDA
19.35
Overvalued EV/EBITDA
26.91
Undervalued EV/EBITDA
15.43

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
2.44
Current PS
3.35
Overvalued PS
3.06
Undervalued PS
1.82

Financials

Annual
Quarterly
FY2025Q1
YoY :
+1.59%
98.98M
Total Revenue
FY2025Q1
YoY :
-108.28%
-655.00K
Operating Profit
FY2025Q1
YoY :
-106.70%
-505.00K
Net Income after Tax
FY2025Q1
YoY :
-106.25%
-0.01
EPS - Diluted
FY2025Q1
YoY :
+126.18%
-20.59M
Free Cash Flow
FY2025Q1
YoY :
-0.59%
64.23
Gross Profit Margin - %
FY2025Q1
YoY :
-103.79%
-0.11
FCF Margin - %
FY2025Q1
YoY :
-106.60%
-0.51
Net Margin - %
FY2025Q1
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.1M
USD
6
3-6
Months
3.3M
USD
9
6-9
Months
1.9M
USD
7
0-12
Months
952.0K
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
2
53.1K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

AORT News & Events

Events Timeline

2025-05-05 (ET)
2025-05-05
16:09:18
Artivion raises FY25 revenue view to $423M-$435M, consensus $423.7M
select
2025-05-05
16:07:55
Artivion reports Q1 adjusted EPS 6c, consensus 5c
select
2025-05-05
07:12:15
Artivion announces presentation of Nexus device trial results
select
Sign Up For More Events

News

9.5
07-24PRnewswire
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results
4.0
06-17Benzinga
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
5.0
06-17NASDAQ.COM
Insider Sale: SVP of $AORT Sells 14,306 Shares
Sign Up For More News

FAQ

arrow icon

What is Artivion Inc (AORT) stock price today?

The current price of AORT is 31.67 USD — it has increased 0.54 % in the last trading day.

arrow icon

What is Artivion Inc (AORT)'s business?

arrow icon

What is the price predicton of AORT Stock?

arrow icon

What is Artivion Inc (AORT)'s revenue for the last quarter?

arrow icon

What is Artivion Inc (AORT)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Artivion Inc (AORT)'s fundamentals?

arrow icon

How many employees does Artivion Inc (AORT). have?

arrow icon

What is Artivion Inc (AORT) market cap?